Upgrade StorageSame Reference Number Being Used for Different Sources and Reference List Restarting Partway Through
I'm having trouble with my in text references and bibliography list. The reference list appears to be glitching for some reason and adding the same number to different citations. I am using AMA style and have automatic citation updates selected in the document preferences. I noticed this issue before so deleted all references and started fresh by manually inputting each again. The same issue occurred.
Here is the bibliography list. You can see that there are two different sources for #2 and the list goes 1-8 before restarting at 3-19.
1. Bouvard V, Wentzensen N, Mackie A, et al. The IARC Perspective on Cervical Cancer Screening. The new england journal of medicine. Published online 2021.
2. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. The Journal of Pediatrics. 1998;132(2):277-284. doi:10.1. Mayrand MH, Hanley J, Franco EL. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. n engl j med. Published online 2007.
2. Simkin J, Smith L, Van Niekerk D, et al. Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004–2013: a descriptive study. cmajo. 2021;9(2):E424-E432. doi:10.9778/cmajo.20200139
3. Cervical Cancer Symptoms. National Cancer Institute. https://www.cancer.gov/types/cervical/symptoms
4. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. Published online April 3, 2019:l1161. doi:10.1136/bmj.l1161
5. Batmunkh T, Dalmau MT, Munkhsaikhan ME, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020;38(27):4316-4324. doi:10.1016/j.vaccine.2020.04.041
6. Barnabas RV, Brown ER, Onono MA, et al. Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. NEJM Evidence. 2022;1(5). doi:10.1056/EVIDoa2100056
7. Watson-Jones D, Changalucha J, Whitworth H, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet Global Health. 2022;10(10):e1473-e1484. doi:10.1016/S2214-109X(22)00309-6
8. Arbyn M, Castle PE, Schiffman M, Wentzensen N, Heckman‐Stoddard B, Sahasrabuddhe VV. Meta‐analysis of agreement/concordance statistics in studies comparing self‐ vs clinician‐collected samples for HPV testing in cervical cancer screening. Intl Journal of Cancer. 2022;151(2):308-312. doi:10.1002/ijc.33967
1016/S0022-3476(98)70445-7
3. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. The Lancet. 2001;357(9271):1831-1836. doi:10.1016/S0140-6736(00)04956-4
4. Moscicki AB. Management of Adolescents Who Have Abnormal Cytology and Histology. Obstetrics and Gynecology Clinics of North America. 2008;35(4):633-643. doi:10.1016/j.ogc.2008.09.004
5. Kjaer SK. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325(7364):572-572. doi:10.1136/bmj.325.7364.572
6. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. JNCI Journal of the National Cancer Institute. 2010;102(19):1478-1488. doi:10.1093/jnci/djq356
7. Human Papillomavirus (HPV) Vaccines: Canadian Immunization Guide. Health Canada Accessed November 15, 2023. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html#p4c8a2
8. Statistics by Cancer Type - Cervix. BC Cancer; 2021:2. Accessed November 15, 2023. http://www.bccancer.bc.ca/statistics-and-reports-site/Documents/Cancer_Type_Cervix_2018_20210305.pdf
9. Simkin J, Smith L, Van Niekerk D, et al. Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004–2013: a descriptive study. cmajo. 2021;9(2):E424-E432. doi:10.9778/cmajo.20200139
10. McGahan CE, Linn K, Guno P, et al. Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010. Cancer Causes Control. 2017;28(10):1105-1116. doi:10.1007/s10552-017-0950-7
11. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—A systematic review & meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020;247:163-175. doi:10.1016/j.ejogrb.2020.02.014
12. Gates A, Pillay J, Reynolds D, et al. Screening for the prevention and early detection of cervical cancer: protocol for systematic reviews to inform Canadian recommendations. Syst Rev. 2021;10(1):2. doi:10.1186/s13643-020-01538-9
13. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
14. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? The Journal of Pathology. 2014;234(4):431-435. doi:10.1002/path.4424
15. The cobas® HPV Test. Diagnostics. Accessed February 7, 2024. https://diagnostics.roche.com/global/en/products/params/cobas-hpv.html
16. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd ed. World Health Organization; 2014. Accessed November 17, 2023. https://iris.who.int/handle/10665/144785
17. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7
18. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors: Journal of Lower Genital Tract Disease. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525
19. Cuzick J, Clavel C, Petry K, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Intl Journal of Cancer. 2006;119(5):1095-1101. doi:10.1002/ijc.21955
Here is the bibliography list. You can see that there are two different sources for #2 and the list goes 1-8 before restarting at 3-19.
1. Bouvard V, Wentzensen N, Mackie A, et al. The IARC Perspective on Cervical Cancer Screening. The new england journal of medicine. Published online 2021.
2. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. The Journal of Pediatrics. 1998;132(2):277-284. doi:10.1. Mayrand MH, Hanley J, Franco EL. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. n engl j med. Published online 2007.
2. Simkin J, Smith L, Van Niekerk D, et al. Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004–2013: a descriptive study. cmajo. 2021;9(2):E424-E432. doi:10.9778/cmajo.20200139
3. Cervical Cancer Symptoms. National Cancer Institute. https://www.cancer.gov/types/cervical/symptoms
4. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. Published online April 3, 2019:l1161. doi:10.1136/bmj.l1161
5. Batmunkh T, Dalmau MT, Munkhsaikhan ME, et al. A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination. Vaccine. 2020;38(27):4316-4324. doi:10.1016/j.vaccine.2020.04.041
6. Barnabas RV, Brown ER, Onono MA, et al. Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. NEJM Evidence. 2022;1(5). doi:10.1056/EVIDoa2100056
7. Watson-Jones D, Changalucha J, Whitworth H, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet Global Health. 2022;10(10):e1473-e1484. doi:10.1016/S2214-109X(22)00309-6
8. Arbyn M, Castle PE, Schiffman M, Wentzensen N, Heckman‐Stoddard B, Sahasrabuddhe VV. Meta‐analysis of agreement/concordance statistics in studies comparing self‐ vs clinician‐collected samples for HPV testing in cervical cancer screening. Intl Journal of Cancer. 2022;151(2):308-312. doi:10.1002/ijc.33967
1016/S0022-3476(98)70445-7
3. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. The Lancet. 2001;357(9271):1831-1836. doi:10.1016/S0140-6736(00)04956-4
4. Moscicki AB. Management of Adolescents Who Have Abnormal Cytology and Histology. Obstetrics and Gynecology Clinics of North America. 2008;35(4):633-643. doi:10.1016/j.ogc.2008.09.004
5. Kjaer SK. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325(7364):572-572. doi:10.1136/bmj.325.7364.572
6. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. JNCI Journal of the National Cancer Institute. 2010;102(19):1478-1488. doi:10.1093/jnci/djq356
7. Human Papillomavirus (HPV) Vaccines: Canadian Immunization Guide. Health Canada Accessed November 15, 2023. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-9-human-papillomavirus-vaccine.html#p4c8a2
8. Statistics by Cancer Type - Cervix. BC Cancer; 2021:2. Accessed November 15, 2023. http://www.bccancer.bc.ca/statistics-and-reports-site/Documents/Cancer_Type_Cervix_2018_20210305.pdf
9. Simkin J, Smith L, Van Niekerk D, et al. Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004–2013: a descriptive study. cmajo. 2021;9(2):E424-E432. doi:10.9778/cmajo.20200139
10. McGahan CE, Linn K, Guno P, et al. Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010. Cancer Causes Control. 2017;28(10):1105-1116. doi:10.1007/s10552-017-0950-7
11. Asthana S, Busa V, Labani S. Oral contraceptives use and risk of cervical cancer—A systematic review & meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2020;247:163-175. doi:10.1016/j.ejogrb.2020.02.014
12. Gates A, Pillay J, Reynolds D, et al. Screening for the prevention and early detection of cervical cancer: protocol for systematic reviews to inform Canadian recommendations. Syst Rev. 2021;10(1):2. doi:10.1186/s13643-020-01538-9
13. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
14. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? The Journal of Pathology. 2014;234(4):431-435. doi:10.1002/path.4424
15. The cobas® HPV Test. Diagnostics. Accessed February 7, 2024. https://diagnostics.roche.com/global/en/products/params/cobas-hpv.html
16. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd ed. World Health Organization; 2014. Accessed November 17, 2023. https://iris.who.int/handle/10665/144785
17. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736(13)62218-7
18. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors: Journal of Lower Genital Tract Disease. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525
19. Cuzick J, Clavel C, Petry K, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Intl Journal of Cancer. 2006;119(5):1095-1101. doi:10.1002/ijc.21955